Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
505.24
-1.50 (-0.30%)
Oct 2, 2026, 2:03 PM EDT - Market open
Vertex Pharmaceuticals Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 128,059 | 115,026 | 103,707 | 104,849 | 74,127 | 55,834 | |
Market Cap Growth | 27.53% | 10.91% | -1.09% | 41.44% | 32.76% | -9.15% |
Enterprise Value | 116,395 | 104,851 | 94,253 | 91,965 | 65,181 | 49,750 |
Last Close Price | 506.74 | 453.36 | 402.70 | 406.89 | 288.78 | 219.60 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 29.49 | 29.10 | - | 28.97 | 22.31 | 23.84 |
Forward PE | 39.17 | 22.61 | 22.66 | 24.44 | 18.83 | 16.42 |
PS Ratio | 10.20 | 9.58 | 9.41 | 10.62 | 8.30 | 7.37 |
PB Ratio | 6.34 | 6.16 | 6.32 | 5.96 | 5.33 | 5.53 |
P/TBV Ratio | 6.85 | 6.71 | 7.15 | 6.70 | 6.07 | 6.42 |
P/FCF Ratio | 33.83 | 36.02 | - | 31.42 | 18.89 | 23.18 |
P/OCF Ratio | 29.92 | 31.68 | - | 29.64 | 17.95 | 21.12 |
PEG Ratio | 2.94 | 0.15 | 1.21 | 1.92 | 0.58 | 1.62 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 9.28 | 8.74 | 8.55 | 9.32 | 7.30 | 6.57 |
EV/EBITDA Ratio | 22.89 | 21.55 | 20.59 | 20.54 | 14.40 | 12.38 |
EV/EBIT Ratio | 23.79 | 22.37 | 21.45 | 21.35 | 14.89 | 12.78 |
EV/FCF Ratio | 30.76 | 32.83 | - | 27.56 | 16.61 | 20.66 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.10 | 0.11 | 0.11 | 0.05 | 0.07 | 0.10 |
Debt / EBITDA Ratio | 0.37 | 0.40 | 0.37 | 0.18 | 0.20 | 0.24 |
Debt / FCF Ratio | 0.52 | 0.64 | - | 0.24 | 0.23 | 0.40 |
Net Debt / Equity Ratio | -0.58 | -0.55 | -0.58 | -0.73 | -0.72 | -0.65 |
Net Debt / EBITDA Ratio | -2.29 | -2.11 | -2.07 | -2.88 | -2.21 | -1.63 |
Net Debt / FCF Ratio | -3.07 | -3.22 | 11.99 | -3.87 | -2.54 | -2.72 |
Asset Turnover | 0.49 | 0.50 | 0.49 | 0.48 | 0.57 | 0.60 |
Inventory Turnover | 3.47 | 3.85 | 5.31 | 7.38 | 8.87 | 8.97 |
Quick Ratio | 2.54 | 2.24 | 2.17 | 3.60 | 4.46 | 4.04 |
Current Ratio | 3.19 | 2.90 | 2.69 | 3.99 | 4.83 | 4.46 |
Return on Equity (ROE) | 23.54% | 22.54% | -3.15% | 22.99% | 27.67% | 24.93% |
Return on Assets (ROA) | 11.93% | 12.16% | 12.14% | 13.17% | 17.33% | 19.32% |
Return on Invested Capital (ROIC) | 28.80% | 30.54% | -98.60% | 63.54% | 90.72% | 102.53% |
Return on Capital Employed (ROCE) | 20.90% | 21.50% | 23.20% | 22.50% | 28.40% | 34.50% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 2, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 3.43% | 3.44% | -0.52% | 3.45% | 4.48% | 4.20% |
FCF Yield | 2.96% | 2.78% | -0.76% | 3.18% | 5.29% | 4.31% |
Buyback Yield / Dilution | 0.85% | -0.04% | 1.00% | -0.54% | 0.31% | 1.33% |